Correction for De Groote et al., “Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection”

Mary Ann De Groote,a,b Michael Higgins,c Thomas Hraha,a Kirsten Wall,a Michael L. Wilson,c David G. Sterling,a Nebojsa Janjic,a Randall Reves,d Urs A. Ochsner,a Robert Belknapd

SomaLogic, Inc., Boulder, Colorado, USAa; Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USAb; Department of Pathology and Laboratory Services, Denver Health, Denver, Colorado, USAc; Denver Health and Hospital Authority and Denver Public Health, Denver, Colorado, USAd

Volume 55, no. 2, p. 391–402, 2017, https://doi.org/10.1128/JCM.01646-16. Page 400, Materials and Methods, lines 5–10: We retract the statement “The study Prospective comparison of the tuberculin skin test and interferon-gamma release assays in diagnosing infection with Mycobacterium tuberculosis and in predicting progression to tuberculosis’ was approved by the CDC institutional review board (IRB) as CDC protocol 6293.0, and approved by the Colorado multiple IRB (COMIRB) 12-0802 by deferral to the CDC IRB. The approval for using the residual samples for this study was obtained from the TBESC parent study investigators.” It should be replaced with the statement “There was no formal mechanism in place at the time of this study for obtaining TBESC approval. We did confirm verbally that the specimens were not needed for other purposes and subsequently proceeded to obtain research approval from our local Institutional Review Board to use these discarded clinical samples as described.”

Copyright © 2017 American Society for Microbiology. All Rights Reserved.